NovAb, Inc.
NOVAB is a biotechnology company specializing in innovative monoclonal antibodies and multimeric ligand technology. Their mission is to develop new diagnostic and therapeutic functions through a novel class of small, single polypeptide antibodies with distinctive rigid β-sheet binding sites. They focus on accessing targets that are different from conventional antibodies, including glycans, and enabling high sensitivity detection and targeting of infectious agents and tumor cells. Their technologies also include cell and tissue-specific targeting and delivery of various agents. The company is led by founders Max D. Cooper, M.D., a renowned immunologist, and L. Edward Cannon, Ph.D., an experienced biotech executive.
Industries
Nr. of Employees
small (1-50)
Services
Antibody discovery and engineering platform for glycan targets
Platform services to discover and engineer antibodies that recognize glycan epitopes and discriminate closely related carbohydrate structures.
Custom development of multispecific antibodies and antibody polymers
Development of multispecific constructs and polymeric antibody formats for increased detection sensitivity and targeted binding to pathogens or tumor cells.
Multimeric ligand–based targeting and delivery development
Design and optimization of multimeric ligand constructs for cell- and tissue‑specific targeting and for delivery of payloads such as drugs and nucleic acid modifiers.
Antibody discovery and engineering platform for glycan targets
Platform services to discover and engineer antibodies that recognize glycan epitopes and discriminate closely related carbohydrate structures.
Custom development of multispecific antibodies and antibody polymers
Development of multispecific constructs and polymeric antibody formats for increased detection sensitivity and targeted binding to pathogens or tumor cells.
Multimeric ligand–based targeting and delivery development
Design and optimization of multimeric ligand constructs for cell- and tissue‑specific targeting and for delivery of payloads such as drugs and nucleic acid modifiers.
Expertise Areas
- Antibody engineering
- Glycobiology and glycan reagent development
- Multispecific biologics
- Targeted delivery systems
Key Technologies
- Single‑polypeptide antibody scaffolds
- Rigid β‑sheet binding‑site design
- Glycan‑targeting antibodies
- Multimeric ligand technology